Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Evolus Inc (EOLS)
NASDAQ:EOLS
Evolus (EOLS) Stock Price & Analysis
465 Followers
EOLS Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$7.07 - $15.43
Previous Close$12.93
Volume425.09K
Average Volume (3M)601.32K
Market Cap
$809.55M
Enterprise Value$839.25M
Total Cash (Recent Filing)$96.96M
Total Debt (Recent Filing)$126.65M
Price to Earnings (P/E)―
Beta1.17
Next Earnings
Jul 31, 2024EPS Estimate
-$0.05Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.04
Shares Outstanding62,610,487
10 Day Avg. Volume363,068
30 Day Avg. Volume601,323
Standard Deviation0.25
R-Squared0.10
Alpha0.00140
Financial Highlights & Ratios
Price to Book (P/B)-16.40
Price to Sales (P/S)4.01
Price to Cash Flow (P/CF)-19.10
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue3.83
Enterprise Value/Gross Profit5.97
Enterprise Value/Ebitda-32.81
Forecast
1Y Price Target
$22.60Price Target Upside74.79% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
Evolus News
PremiumCompany Announcements
Evolus Inc Announces Strategic Board Renewal Plans
Bulls Say, Bears Say
Bulls Say
Financial PerformanceEvolus reported strong quarterly results, with total sales significantly exceeding market expectations, demonstrating a robust demand for Jeuveau.
Market ExpansionEvolus plans to launch Nuceiva in additional countries, including Australia and Spain, potentially increasing its market presence.
Product ApprovalEvolysse products demonstrated superiority to Restylane at 6 months and improvement in key secondary endpoints, supporting the Premarket Approval application to the FDA.
Bears Say
Financial PerformanceThe higher spending resulted in a wider non-GAAP EPS loss, indicating financial performance below market expectations.
Market CompetitionThe company's ability to capture market share could be hindered by competitive response, especially from larger competitors.
Supply Chain IssuesKey risks include disruption to supply chain, which could lead to operational challenges and affect the company's ability to meet demand.
---
Ownership Overview
16.57% Insiders
8.64% Mutual Funds
55.99% Other Institutional Investors
18.79% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
EOLS FAQ
What was Evolus Inc’s price range in the past 12 months?
Evolus Inc lowest stock price was $7.07 and its highest was $15.43 in the past 12 months.
What is Evolus Inc’s market cap?
Currently, no data Available
When is Evolus Inc’s upcoming earnings report date?
Evolus Inc’s upcoming earnings report date is Jul 31, 2024 which is in 59 days.
How were Evolus Inc’s earnings last quarter?
Evolus Inc released its earnings results on May 07, 2024. The company reported -$0.083 earnings per share for the quarter, beating the consensus estimate of -$0.152 by $0.069.
Is Evolus Inc overvalued?
According to Wall Street analysts Evolus Inc’s price is currently Undervalued.
Does Evolus Inc pay dividends?
Evolus Inc does not currently pay dividends.
What is Evolus Inc’s EPS estimate?
Evolus Inc’s EPS estimate is -$0.05.
How many shares outstanding does Evolus Inc have?
Evolus Inc has 62,610,490 shares outstanding.
What happened to Evolus Inc’s price movement after its last earnings report?
Evolus Inc reported an EPS of -$0.083 in its last earnings report, beating expectations of -$0.152. Following the earnings report the stock price went down -1.192%.
Which hedge fund is a major shareholder of Evolus Inc?
Among the largest hedge funds holding Evolus Inc’s share is Perceptive Advisors LLC. It holds Evolus Inc’s shares valued at 81M.
---
Evolus Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$22.60 (74.79% Upside)
$22.60 (74.79% Upside)
Blogger Sentiment
Bullish
EOLS Sentiment 75%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Increased
By 2.0M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $2.7M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 0.4%
Last 30 Days ▲ 5.9%
Last 30 Days ▲ 5.9%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
42.87%
12-Months-Change
Fundamentals
Return on Equity
-472.61%
Trailing 12-Months
Asset Growth
41.15%
Trailing 12-Months
Company Description
Evolus Inc
Evolus, Inc. is a medical aesthetics company, which engages in the provision of medical aesthetic treatments and procedures. It offers products under the brand of Jeuveau. The company was founded by Scott Cannizzaro in November, 2012 and is headquartered in Newport Beach, CA.
---
EOLS Company Deck
---
EOLS Earnings Call
Q1 2024
0:00 / 0:00
---
EOLS Stock 12 Month Forecast
Average Price Target
$22.60
▲(74.79% Upside)
Technical Analysis
Best Analysts Covering EOLS
1 Year
1 Year Success Rate
13/21 ratings generated profit
1 Year Average Return
+13.22%
reiterated a buy rating 12 days ago
Copying Douglas Tsao's trades and holding each position for 1 Year would result in 61.90% of your transactions generating a profit, with an average return of +13.22% per trade.
---